Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects

Stroke

Volumn 38, Issue 3, 2007, Pages 1036-1043

  López Atalaya, José P ^a,b,c   Roussel, Benoit D ^a,b,c   Ali, Carine ^a,b,c   Maubert, Eric ^a,b,c   Petersen, Karl Uwe ^d   Berezowski, Vincent ^e   Cecchelli, Roméo ^e   Orset, Cyrille ^a,b,c   Vivien, Denis ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c GIP CYCERON   (France)

^d PAION Deutschland GmbH   (Germany)

^e UNIVERSITÉ D'ARTOIS   (France)

Author keywords

Blood brain barrier; Desmoteplase; Excitotoxicity; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; DESMOTEPLASE; GLUCOSE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N METHYL DEXTRO ASPARTIC ACID; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; SALIVARY PLASMINOGEN ACTIVATOR ALPHA 1, DESMODUS ROTUNDUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAT; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DESMODUS ROTUNDUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TRANSPORT; EXCITOTOXICITY; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; ANIMAL; CATTLE; CELL CULTURE; COCULTURE; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CATTLE; CELLS, CULTURED; CHIROPTERA; COCULTURE TECHNIQUES; FIBRINOLYTIC AGENTS; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; MALE; PLASMINOGEN ACTIVATORS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 33947543221     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000258100.04923.84     Document Type: Article

References (28)

1. Hacke W, Donnan G, Fieschi C, Kaste M., von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. ATLANTIS Trial Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
3. Schleuning WD, Alagon A, Boidol W, Bringmann P, Petri T, Kratzschmar J, Haendler B, Langer G, Baldus B, Witt W, Donner P. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci. 1992;667:395-403.
4. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
5. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
6. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003;34:537-543.
7. Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, Petersen KU, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke. 2005;36:1241-1246.
8. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 2004;27:155-160.
9. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab. 2004;24:945-963.
10. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317.
11. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J, Chuquet J, Nouvelot A, MacKenzie ET, Bu G, Cecchelli R, Touzani O, Vivien D. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation. 2005;111:2241-2249.
12. Benchenane K, Berezowski V, Fernandez-Monreal M, Brillault J, Valable S, Dehouck MP, Cecchelli R, Vivien D, Touzani O, Ali C. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke. 2005;36:1065-1070.
13. Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer V, Duhem C, Lundquist S, Rentfel M, Torpier G, Dehouck MP. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:165-178.
14. Brillault J, Berezowski V, Cecchelli R, Dehouck MP. Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood-brain barrier during ischaemia. J Neurochem. 2002;83:807-817.
15. Bringmann P, Gruber D, Liese A, Toschi L, Krätzschmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem. 1995;270:25596-25603.
16. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature. 1995;377:340-344.
17. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
18. Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke. 2004;35:354-356.
19. Godfrey KR, Tanswell P, Bates RA, Chappell MJ, Madden FN. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models. Biopharm Drug Dispos. 1998;19:131-140.
20. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779-784.
21. Orth K, Willnow T, Herz J, Gething MJ, Sambrook J. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem. 1994;269:21117-21122.
22. Chen ZL, Indyk JA, Bugge TH, Kombrinck KW, Degen JL, Strickland S. Neuronal death and blood-brain barrier breakdown after excitotoxic injury are independent processes. J Neurosci. 1999;19:9813-9820.
23. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl- D-aspartate receptor signalling. J Biol Chem. 2004;279:50850-50856.
24. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman SN, Higazi AA. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood. 2004;103:897-902.
25. Armstead WM, Cines DB, Higazi AA. Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury. J Neurotrauma. 2004;21:1204-1211.
26. Akkawi S, Nassar T, Tarshis M, Cines DB, Higazi AA. LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol. 2006;291:H1351-H1359.
27. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke. 2006;37:1910-1912.
28. Biessen EA, van Teijlingen M, Vietsch H, Barrett-Bergshoeff MM, Bijsterbosch MK, Rijken DC, van Berkel TJ, Kuiper J. Antagonist of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation. 1997;95:46-52.